Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.
Transthera Biosciences Co. Ltd. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Merck Sharp & Dohme LLC has synthesized viral replication inhibitors reported to be useful for the treatment of respiratory syncytial virus and metapneumovirus infections.
Prelude Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and more.
The widespread need for cartilage repair may have bred optimism on the part of Spinalcyte LLC when it filed a related patent in 2014, but the Patent Trial and Appeal Board has affirmed a rejection of the patent due to lack of enablement, an object lesson regarding the need for clarity in patent applications.
Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.
University of Arizona has identified non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
RSS
